PortalPublikationenAssociation of diabetes mellitus and metformin use with bioc...

Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer

Standard

Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. / Rieken, Malte; Kluth, Luis A; Xylinas, Evanguelos; Fajkovic, Harun; Becker, Andreas; Karakiewicz, Pierre I; Herman, Michael; Lotan, Yair; Seitz, Christian; Schramek, Paul; Remzi, Mesut; Loidl, Wolfgang; Pummer, Karl; Lee, Richard K; Faison, Talia; Scherr, Douglas S; Kautzky-Willer, Alexandra; Bachmann, Alexander; Tewari, Ashutosh; Shariat, Shahrokh F.

in: WORLD J UROL, Jahrgang 32, Nr. 4, 01.08.2014, S. 999-1005.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rieken, M, Kluth, LA, Xylinas, E, Fajkovic, H, Becker, A, Karakiewicz, PI, Herman, M, Lotan, Y, Seitz, C, Schramek, P, Remzi, M, Loidl, W, Pummer, K, Lee, RK, Faison, T, Scherr, DS, Kautzky-Willer, A, Bachmann, A, Tewari, A & Shariat, SF 2014, 'Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer', WORLD J UROL, Jg. 32, Nr. 4, S. 999-1005. https://doi.org/10.1007/s00345-013-1171-7

APA

Rieken, M., Kluth, L. A., Xylinas, E., Fajkovic, H., Becker, A., Karakiewicz, P. I., Herman, M., Lotan, Y., Seitz, C., Schramek, P., Remzi, M., Loidl, W., Pummer, K., Lee, R. K., Faison, T., Scherr, D. S., Kautzky-Willer, A., Bachmann, A., Tewari, A., & Shariat, S. F. (2014). Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. WORLD J UROL, 32(4), 999-1005. https://doi.org/10.1007/s00345-013-1171-7

Vancouver

Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI et al. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. WORLD J UROL. 2014 Aug 1;32(4):999-1005. https://doi.org/10.1007/s00345-013-1171-7

Bibtex

@article{b5c3c519245b4349b33720f20175bb5a,
title = "Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer",
abstract = "PURPOSE: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.METHODS: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR.RESULTS: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabetic patients without metformin use, and 85 % for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR.CONCLUSIONS: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.",
author = "Malte Rieken and Kluth, {Luis A} and Evanguelos Xylinas and Harun Fajkovic and Andreas Becker and Karakiewicz, {Pierre I} and Michael Herman and Yair Lotan and Christian Seitz and Paul Schramek and Mesut Remzi and Wolfgang Loidl and Karl Pummer and Lee, {Richard K} and Talia Faison and Scherr, {Douglas S} and Alexandra Kautzky-Willer and Alexander Bachmann and Ashutosh Tewari and Shariat, {Shahrokh F}",
year = "2014",
month = aug,
day = "1",
doi = "10.1007/s00345-013-1171-7",
language = "English",
volume = "32",
pages = "999--1005",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer

AU - Rieken, Malte

AU - Kluth, Luis A

AU - Xylinas, Evanguelos

AU - Fajkovic, Harun

AU - Becker, Andreas

AU - Karakiewicz, Pierre I

AU - Herman, Michael

AU - Lotan, Yair

AU - Seitz, Christian

AU - Schramek, Paul

AU - Remzi, Mesut

AU - Loidl, Wolfgang

AU - Pummer, Karl

AU - Lee, Richard K

AU - Faison, Talia

AU - Scherr, Douglas S

AU - Kautzky-Willer, Alexandra

AU - Bachmann, Alexander

AU - Tewari, Ashutosh

AU - Shariat, Shahrokh F

PY - 2014/8/1

Y1 - 2014/8/1

N2 - PURPOSE: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.METHODS: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR.RESULTS: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabetic patients without metformin use, and 85 % for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR.CONCLUSIONS: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.

AB - PURPOSE: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial.METHODS: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR.RESULTS: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin. DM and metformin were not associated with any clinicopathologic features (p values >0.05). Within a median follow-up of 25 months (interquartile range 35 months), 774 (11.3 %) patients experienced BCR. Actuarial 5-year biochemical-free survival was 83 % for non-diabetic, 79 % for diabetic patients without metformin use, and 85 % for diabetic patients with metformin use (log rank p = 0.17). In uni- and multivariable Cox regression analyses with the non-diabetic group as referent, DM without metformin use (HR = 0.99; 95 % CI 0.75-1.30, p = 0.65) and DM with metformin use (HR = 0.84, 95 % CI 0.58-1.22, p = 0.36) were not associated with BCR after RP. A subgroup analysis stratified by nodal status, surgical margins, tumor stage, and Gleason sum did not reveal any significant association between DM, use of metformin and risk of BCR.CONCLUSIONS: We found no association between DM or metformin use and cancer-specific features or BCR in patients treated with RP. The effect of DM and metformin on complications, wound healing and overall survival needs to be assessed in similar cohorts.

U2 - 10.1007/s00345-013-1171-7

DO - 10.1007/s00345-013-1171-7

M3 - SCORING: Journal article

C2 - 24062093

VL - 32

SP - 999

EP - 1005

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 4

ER -